Navigation Links
Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
Date:10/8/2008

expected benefits of Transcept product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Transcept Pharmaceuticals Appoints Key Senior Executives
2. Transcept Pharmaceuticals to Participate in Middle-of-the-Night (MOTN) Insomnia Investor Panel
3. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
8. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
9. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
10. Alseres Pharmaceuticals, Inc. Raises $5 Million
11. Stason Pharmaceuticals, Inc. Appoints Diana Wood as Vice President, Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... N.J. , Aug. 31, 2014 Wockhardt ... Drug Discovery program in Anti-Infective research when two of ... coveted Qualified Infectious Disease Product (QIDP) status from U.S. ... to drugs which act against pathogens which have a ... are identified by Centre for Disease Control (a top ...
(Date:8/31/2014)... This is a professional and ... Epoxy Hardener industry in Global and China. ... industry, including definitions, applications and industry chain structure. ... are provided with a focus on history, developments, ... comparison between the international and Chinese situation is ...
(Date:8/29/2014)... are based on electrons, but one of the most ... i.e. circuits based on light (photons) instead of electrons. ... a stream of single photons and control their direction. ... attempts to achieve this control, but now scientists at ... steady stream of photons emitted one at a time ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2
... Lentigen Corporation, a biotechnology company specializing in the ... and Expression Therapeutics, a biotechnology company specializing in ... to co-develop novel cell and protein therapies for ... disorder caused by a mutation in the factor ...
... Kendle (Nasdaq: KNDL ) announced today that ... the market closes on Tuesday, Feb. 24, 2009. The Company ... Wednesday, Feb. 25 at 8:30 a.m. Eastern Time. A question ... , To participate in the telephone conference call, interested parties ...
... Feb. 4 On the heels of a strong start ... executives will explain to investors this month where the company ... this year and how it plans to achieve its goal ... by fiscal 2012. Terry Crews, chief financial officer, and Carl ...
Cached Biology Technology:Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 2Lentigen and Expression Therapeutics Sign Hemophilia Co-Development Agreement 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Monsanto Executives to Discuss Company's Growth Drivers, Profit Goals at Investor Conferences in February 2
(Date:9/1/2014)... how the alteration of a single nucleotidethe basic building block of ... intellectual disability. The study appears in The Journal of ... caused by a defect in a gene on the X chromosome ... in 230 women and 1 in 360 men carry a so-called ... of the FMR1 gene is slightly longer than normal. ...
(Date:8/31/2014)... University of Warwick have discovered that ,good, cholesterol is ... substance, methylglyoxal - MG, was found to damage ,good, ... from the body. , Low levels of HDL, ... with increased levels of MG being common in the ... , Supported by funding from the British Heart Foundation ...
(Date:8/31/2014)... busy attacking us, germs go after each other. But ... for the infected microbes: Sometimes viruses actually carry helpful ... its diet or better attack its own hosts. , ... system would robotically destroy anything it recognized as invading ... now revealed that one variety of the bacterial immune ...
Breaking Biology News(10 mins):A nucleotide change could initiate fragile X syndrome 2Sugar substance 'kills' good HDL cholesterol, new research finds 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3
... & EMS Management Software Provider to Offer Biometrics, ... award-winning,fingerprint biometrics research and development firm, announced today ... Data Systems(R), an,industry leader in the development of ... software and hardware to ZOLL Data,Systems, customers., ...
... 10, 2008 -- The National Institutes of Health (NIH) ... College Assistant Professor of Biology Lara D. Hutson, in ... CMT is the most common inherited neuromuscular disease, ... CMT usually shows dominant inheritance and symptoms generally appear ...
... Human cancer cells divide and conquer. Unless physicians can ... wildly dividing cells will eventually destroy a person,s life. ... an enzyme called telomerase is crucial to cancer,s progress. ... of Georgia,s Franklin College of Arts and Sciences have ...
Cached Biology News:M2SYS Technology Selected by ZOLL Data Systems to Integrate Fingerprint Software 2UGA researchers discover mechanism that explains how cancer enzyme winds up on ends of chromosomes 2
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Request Info...
Biology Products: